Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0021)
Name
Estradiol
Synonyms
estradiol; beta-Estradiol; 17beta-Estradiol; 50-28-2; Oestradiol; Dihydrofolliculin; Estrace; Vivelle; Ovocyclin; progynon; Dihydrotheelin; Dihydroxyestrin; Diogynets; Gynoestryl; Aquadiol; Climara; Diogyn; Gynergon; Vagifem; Dimenformon; Follicyclin; Oestroglandol; Aerodiol; Bardiol; Corpagen; Divigel; Estraderm; Estrovite; Femestral; Ginosedol; Lamdiol; Macrodiol; Oestergon; Ovasterol; Ovastevol; Perlatanol; Primofol; Profoliol; Syndiol; Altrad; Evorel; Dihydromenformon; Estraldine; Estroclim; Estrogel; Menorest; Nordicol; Ovahormon; Femogen; Systen; Zumenon; estradiol-17beta; cis-Estradiol; D-Oestradiol; D-Estradiol; Estraderm TTS; Progynon DH; Climaderm; Compudose; Dermestril; Ovocycline; Trocosone; Estring; Innofem; Oesclim; Alora; Encore; Dihydroxyoestrin; 17beta-Oestradiol; Progynon-DH; Estrasorb; Fempatch; Gynestrel; Gynodiol; Microdiol; Oestrogynal; Ovociclina; Ovocylin; Tradelia; Esclim; Macrol; Menest; Zerella; Estroclim 50; Oestradiol R; SK-Estrogens; Estring vaginal ring; Elestrin; Estrifam; Extrasorb; Ginedisc; Estreva; Evamist; Femtran; Trial SAT; Theelin, dihydro-; GynPolar; Compudose 200; Compudose 365; Sandrena Gel; Sisare Gel; Estrofem 2; Estradot; Menostar; Oestrogel; Zesteem; 17 beta-Estradiol; Climara Forte; Profoliol B; Estraderm TTS 50; Oestradiol Berco; Estraderm MX; 17b-Oestradiol; VIVELLE-DOT; NSC-9895; Estrapak 50; Estradiol-17-beta; Estradiolum; Estrodiolum; Gelestra; 3,17-Epidihydroxyestratriene; Dihydroxyesterin; cis-Oestradiol; Estrogens, esterified; 17.beta.-Estradiol; B-Estradiol; Epiestriol 50; 17beta oestradiol; Estra-1,3,5(10)-triene-3,17beta-diol; Estradiol Anhydrous; E(sub 2); 17-beta-estradiol; Estradiol-17 beta; Elestrim; Femanest; Femestrol; Minivelle; Yuvvexy; 3,17-Epidihydroxyoestratriene; Sandrena 1; 17b-Estradiol; Estraderm (TN); [3H]-estradiol; 17; A-estradiol; 17; A-Oestradiol; Estrogel (TN); Climara (TN); Divigel (TN); Estrace (TN); Estring (TN); Innofem (TN); Vagifem (TN); Vivelle (TN); (17beta)-Estra-1,3,5(10)-triene-3,17-diol; 17.beta.-Oestradiol; CCRIS 280; CHEBI:16469; HSDB 3589; 3,17.beta.-Estradiol; .beta.-Estradiol; (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; EINECS 200-023-8; .beta.-Oestradiol; [3H]]estradiol; NSC-20293; Estradiol 17-beta; 17-beta-oestradiol; UNII-4TI98Z838E; IMVEXXY; TX-004HR; Estradiol, .beta.-; Estradiol-17.beta.; Estra-1,3,5(10)-triene-3,17-diol (17beta)-; Oestradiol-17.beta.; 17-.beta.-oestradiol; 4TI98Z838E; ESTRADIOL HEMIHYDRATE; Oestra-1,3,5(10)-triene-3,17beta-diol; Estrasorb (TN); 17.beta.-OH-estradiol; 17.beta.-OH-oestradiol; 17beta estradiol (E2); 17beta-Estra-1,3,5(10)-triene-3,17-diol; WC3011; C18H24O2; CHEMBL135; (17beta)-estra-1(10),2,4-triene-3,17-diol; D-3,17.beta.-Estradiol; WC-3011; D-3,17.beta.-Oestradiol; Estra-1,3,5(10)-triene-3,17-diol, (17beta)-; MLS000069494; 3,17b-Dihydroxyestra-1,3,5(10)-triene; (+)-3,17.beta.-Estradiol; 141290-02-0; Oestradiolum; DTXSID0020573; Estradiol valerate metabolite e2; BIJUVA COMPONENT ESTRADIOL; NSC9895; ANGELIQ COMPONENT ESTRADIOL; EC 200-023-8; ORIAHNN COMPONENT ESTRADIOL; PREFEST COMPONENT ESTRADIOL; ACTIVELLA COMPONENT ESTRADIOL; ESTRADIOL COMPONENT OF BIJUVA; COMBIPATCH COMPONENT ESTRADIOL; [3H]E2; ESTRADIOL COMPONENT OF ANGELIQ; ESTRADIOL COMPONENT OF ORIAHNN; ESTRADIOL COMPONENT OF PREFEST; CLIMARA PRO COMPONENT ESTRADIOL; Oestradiol-17beta; (8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; E2; ESTRADIOL COMPONENT OF ACTIVELLA; ESTRADIOL COMPONENT OF COMBIPATCH; Estradiolum [INN]; Estradiolo [DCIT]; NCGC00091544-04; Oestradiol-17-beta; ESTRADIOL COMPONENT OF CLIMARA PRO; Estradiolo; SMR000059126; Estradiol-3,17beta; 17-beta-OH-estradiol; 3,17-beta-Estradiol; 3,17beta-Dihydroxyestra-1,3,5(10)-triene; 3,17-beta-Oestradiol; D-3,17beta-Estradiol; 3,17.beta.-Dihydroxyestra-1,3,5(10)-triene; Methyl 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate.; Benzogynestry; Estropause; Estasorb; (1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-triene-5,14-diol; [2,4,6,7-3H]-E2; E 2; DTXCID80573; ESTRADIOL (USP MONOGRAPH); ESTRADIOL [USP MONOGRAPH]; Destradiol; ESTRADIOL IMPURITY A (IP); ESTRADIOL IMPURITY A [IP]; Zesteen; .alpha.-Estradiol; 17-beta-OH-oestradiol; 17?-Estradiol; D-3,17beta-Oestradiol; D-3,17-beta-Estradiol; Estrodiolum [INN-Latin]; Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-; D-3,17-beta-Oestradiol; Activella (Salt/Mix); Combipatch (Salt/Mix); component of Menrium; Estradiol-17 alpha; Climara Pro (Salt/Mix); 3,17beta-Estradiol; 3,17-.beta.-Oestradiol; Estraderm TTS 100; ETHINYLESTRADIOL IMPURITY D (EP IMPURITY); ETHINYLESTRADIOL IMPURITY D [EP IMPURITY]; 3,3,5(10)-triene; SR-01000075866; 17-.BETA.-Estradiol; 1,3,5-Estratriene-3,17-beta-diol; oestrodiol; Estradiol [USP:INN:BAN]; 3,17beta-Dihydroxyestra-1,3,5-triene; Estradurin; 3,17beta-Dihydroxyoestra-1,3,5-triene; delta-Estradiol; dihydro-Theelin; 3,17-beta-Dihydroxyoestra-1,3,5-triene; NSC20293; beta -estradiol; delta-Oestradiol; Estra-1,3,5(10)-triene-3,17-beta-diol; Estrogel HBF; Oestra-1,3,5(10)-triene-3,17-beta-diol; 1jgl; 1lhu; 1qkt; 1qku; 3,17-beta-Dihydroxyestra-1,3,5(10)-triene; [3H]estradiol; 1,3,5-Estratriene-3,17.beta.-diol; 3,17-beta-Dihydroxy-1,3,5(10)-oestratriene; CAS-50-28-2; 17-beta-Estra-1,3,5(10)-triene-3,17-diol; 17beta-Oestra-1,3,5(10)-triene-3,17-diol; .alpha.-Oestradiol; 17-beta-Oestra-1,3,5(10)-triene-3,17-diol; Estra-1,3,5(10)-triene-3,17-diol; Prestwick_207; 3,17b-Estradiol; Bio-E-Gel; Fem7; [3H]-Estrogen; 17 ?-Estradiol; 3,17.beta.-Dihydroxyestra-1,3,5-triene; 3,17.beta.-Dihydroxyoestra-1,3,5-triene; CMC_11154; Therapeutic Estradiol; 1,3,5,(10)-Estratrien-3,17.beta.-diol; SL-1100; Estra-1,3,5(10)-triene-3,17.beta.-diol; Oestra-1,3,5(10)-triene-3,17.beta.-diol; 2j7x; 3,17.beta.-Dihydroxy-1,3,5(10)-estratriene; 3,17.beta.-Dihydroxy-1,3,5(10)-oestratriene; 3,3,5-triene; [3H]17beta-estradiol; ESTRADIOL [INN]; ESTRADIOL [JAN]; (17?)-Estra-1,3,5(10)-triene-3,17-diol; 17.beta.-Estra-1,3,5(10)-triene-3,17-diol; ESTRADIOL [MI]; ESTRADIOL [HSDB]; ESTRADIOL [INCI]; 17.beta.-Oestra-1,3,5(10)-triene-3,17-diol; Opera_ID_1688; Prestwick0_000441; Prestwick1_000441; Prestwick2_000441; Prestwick3_000441; Spectrum5_002055; 17beta-estradiol (E2); ESTRADIOL [VANDF]; 3,17beta-Dihydroxy-1,3,5(10)-estratriene; alpha-estradiol (obsolete); beta-Estradiol, >=98%; bmse000642; Epitope ID:136018; (+)-3,17b-Estradiol; E 8875; ESTRADIOL [USP-RS]; ESTRADIOL [WHO-DD]; SCHEMBL8049; (+)-3,17beta-Estradiol; Estradiol (JAN/USP/INN); Tritiated estradiol-17-beta; BIDD:PXR0065; Lopac0_000503; S-21400; BSPBio_000482; BSPBio_001065; KBioGR_000405; KBioGR_002269; KBioSS_000405; KBioSS_002270; MLS000758312; MLS001076331; MLS001424022; BIDD:ER0125; SPBio_002421; ESTRADIOL [GREEN BOOK]; BPBio1_000532; GTPL1012; GTPL1013; ESTRADIOL [ORANGE BOOK]; NIOSH/KG7030000; BDBM17292; KBio2_000405; KBio2_002269; KBio2_002973; KBio2_004837; KBio2_005541; KBio2_007405; KBio3_000769; KBio3_000770; KBio3_002749; 1a52; 1g50; 2d06; cMAP_000005; Bio1_000403; Bio1_000892; Bio1_001381; Bio2_000363; Bio2_000843; HMS1362E07; HMS1569I04; HMS1792E07; HMS1990E07; HMS2051C17; HMS2090E18; HMS2096I04; HMS2236H04; HMS3261F07; HMS3403E07; HMS3713I04; HMS3884A08; beta-Estradiol, analytical standard; (8S,9S,13S,14S,17S)-13-Methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; BCP08579; ESTRADIOL 17-BETA [VANDF]; HY-B0141; Tox21_111148; Tox21_202057; Tox21_300288; Tox21_500503; 1,5-Estratriene-3,17.beta.-diol; HB2494; LMST02010001; s1709; Estradiol-17-beta-6,7-(sup 3)H; [2,4,6,7-3H]-17beta-estradiol; AKOS015896570; CCG-100808; CS-1938; DB00783; LP00503; NC00058; SDCCGSBI-0050487.P002; IDI1_002118; SMP1_000121; NCGC00091544-00; NCGC00091544-01; NCGC00091544-02; NCGC00091544-05; NCGC00091544-06; NCGC00091544-07; NCGC00091544-09; NCGC00091544-10; NCGC00091544-11; NCGC00091544-12; NCGC00091544-13; NCGC00091544-14; NCGC00091544-15; NCGC00091544-16; NCGC00091544-18; NCGC00091544-27; NCGC00179321-01; NCGC00179321-02; NCGC00254177-01; NCGC00259606-01; NCGC00261188-01; 17-E; AC-22346; AS-13729; CPD000059126; Estra-1,3,5(10)-triene-3,17b-diol; Oestra-1,3,5(10)-triene-3,17b-diol; WLN: L E5 B666TTT&J E1 FQ OQ; 17 beta-Estradiol, 1mg/ml in Acetonitrile; Estra-1,5(10)-triene-3,17.beta.-diol; Estradiol, meets USP testing specifications; 3,17beta-dihydroxyestra-1,3,5(10)-trien; EU-0100503; KG70300000; Oestra-1,5(10)-triene-3,17.beta.-diol; C00951; D00105; EN300-119518; (17b)-Estra-1,3,5(10)-triene-3,17-diol; 13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol; 17.beta.-Estra-1,5(10)-triene-3,17-diol; 17.beta.-Oestra-1,5(10)-triene-3,17-diol; 17-beta-Estradiol 100 microg/mL in Acetonitrile; Q422416; SR-01000721892; 13beta-Methyl-1,3,5(10)-gonatriene-3,17beta-ol; Estra-1,5(10)-triene-3,17-diol (17.beta.)-; ESTRADIOL BENZOATE IMPURITY A [EP IMPURITY]; ESTRADIOL VALERATE IMPURITY A [EP IMPURITY]; Q-201503; SR-01000075866-1; SR-01000075866-4; SR-01000721892-3; BRD-K18910433-001-04-4; BRD-K18910433-001-43-2; estra-1(10),2,4-triene-3,17-diol, (17beta)-; Estra-1,5(10)-triene-3,17-diol, (17.beta.)-; Z1521553843; B8B5AEF5-4957-49EB-A14F-444A8212C482; beta-Estradiol, BioReagent, powder, suitable for cell culture; Estradiol, United States Pharmacopeia (USP) Reference Standard; 13.BETA.-METHYL-1,3,5(10)-GONATRIENE-3,17.BETA.-OL; beta-Estradiol, powder, gamma-irradiated, suitable for cell culture; Estra-1,3,5(10)-triene-3,17-diol, (6,7-(sup 3)H,17-beta)-; (9beta,13alpha,14beta,17alpha)-estra-1,3,5(10)-triene-3,17-diol; Estradiol, Pharmaceutical Secondary Standard; Certified Reference Material; (13S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-beta-diol; (1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-2,4,6-triene-5,14-diol; (1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2,4,6-triene-5,14-diol

    Click to Show/Hide
Structure
Formula
C18H24O2
IUPAC Name
(8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
Canonical SMILES
CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O
InChI
InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
InChIKey
VOXZDWNPVJITMN-ZBRFXRBCSA-N
PubChem CID
5757
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Acute kidney failure ICD-11: GB60
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model CHO-S/H9C2 cells Normal Cricetulus griseus CVCL_A0TS
NRK-49F cells Normal Rattus norvegicus CVCL_2144
HK-2 cells Normal Homo sapiens CVCL_0302
C2C12 cells Normal Mus musculus CVCL_0188
MDA-MB-231 cells Breast adenocarcinoma Homo sapiens CVCL_0062
NRK-52E cells Normal Rattus norvegicus CVCL_0468
LLC-PK1 cells Normal Sus scrofa CVCL_0391
PANC-1 cells Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
HT22 cells Normal Mus musculus CVCL_0321
hUPECs (Human urine-derived podocyte-like epithelial cells)
In Vivo Model
C57BL/6N male mice (CLEA Japan), aged 8-9 weeks, were used. AKI was induced by intraperitoneal injection of cisplatin solution (16 or 17 mg/kg as indicated; Nichi-Iko Pharmaceutical). Mice were orally treated with water only, promethazine (20 mg/kg in water), or rifampicin (20 mg/kg in 0.5% methylcellulose) every 12 hours for 4 days starting 30 minutes before the cisplatin injection, or orally treated with promethazine (20 mg/kg) in the following groups: (1) no promethazine, (2) pretreatment 30 minutes before cisplatin injection, (3) treatment from 30 minutes before injection to 24 hours after injection, (4) treatment from 24 to 96 hours after injection, and (5) treatment every 12 hours from 30 minutes before injection to 96 hours after injection.

    Click to Show/Hide
Response regulation Eight drugs and hormones that showed antiferroptotic activity, including omeprazole, indole-3-carbinol, rifampicin, promethazine, carvedilol, propranolol, estradiol, and triiodothyronine. Moreover, in mice, the drugs ameliorated acute kidney injury and liver injury, with suppression of tissue lipid peroxidation and decreased cell death.
References
Ref 1 Drugs Repurposed as Antiferroptosis Agents Suppress Organ Damage, Including AKI, by Functioning as Lipid Peroxyl Radical Scavengers. J Am Soc Nephrol. 2020 Feb;31(2):280-296. doi: 10.1681/ASN.2019060570. Epub 2019 Nov 25.